Adam Crystal - 04 Jan 2022 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
04 Jan 2022
Net transactions value
-$377,618
Form type
4
Filing time
05 Jan 2022, 15:30:21 UTC
Previous filing
23 Dec 2021
Next filing
16 Feb 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Options Exercise $97,350 +15,000 +100% $6.49 30,000 04 Jan 2022 Direct F1
transaction CCCC Common Stock Sale $440,547 -13,946 -46% $31.59* 16,054 04 Jan 2022 Direct F1, F2
transaction CCCC Common Stock Sale $34,420 -1,054 -6.6% $32.66* 15,000 04 Jan 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -15,000 -12% $0.000000 112,292 04 Jan 2022 Common Stock 15,000 $6.49 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.32 to $33.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter.